Clinical Trials
126 trialsA Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
MASTER-2
University of Alabama at Birmingham
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
LBL 2018
University Hospital Muenster
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
VIWA-1
University of Ulm
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Memorial Sloan Kettering Cancer Center
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
ADGP
Second Affiliated Hospital, School of Medicine, Zhejiang University
ADTD
Second Affiliated Hospital, School of Medicine, Zhejiang University
ADDC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center
MAGENTA
Massachusetts General Hospital
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Memorial Sloan Kettering Cancer Center
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
BOREALIS
Canadian Myeloma Research Group
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Iber-KDd
University of Miami
RESPIRE-ILD
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
PILDI
Institute of Oncology Ljubljana
ADORATION
Baptist Health South Florida
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
BRAINS
The Netherlands Cancer Institute
SELVEDge
University of Miami
Glo-BNHL
University of Birmingham
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CarMob
Hackensack Meridian Health
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Children's Hospital Medical Center, Cincinnati
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center